Seven major European drugmakers--including Bayer, Johnson & Johnson ($JNJ), Sanofi ($SNY) and AstraZeneca ($AZN)--joined with other pharma companies, academics and other collaborators in a €196 million ($262.6 million) project to share and screen hundreds of thousands of compounds. Report